Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

TRAIL gene expression analysis in multiple sclerosis patients

TRAIL gene expression analysis in multiple sclerosis patients BACKGROUND: Multiple sclerosis (MS) as an autoimmune disorder inwhich the insulating covers of neurons in the Central Nervous System aredestructed. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)is an immunomodulatory molecule to protect against T cells hyper activation.METHODS: In this Case-control study, we compare TRAIL geneexpression in peripheral blood between 50 relapse remitting MS patients and50 healthy controls by TaqMan Real time PCR. All the patients were negativefor HLA-DRB1*15 susceptible allele, normal serum vitamin D, responder toInterferon beta. All the health individuals were matched to patients. Also,we tried to find correlation between TRAIL gene expression and clinicalcharacteristics of patients.RESULTS: No statistically significantdifference was found in TRAIL mRNA expression between MS patients andcontrols (p> 0.05). There was no correlation in the TRAIL expression and ageof onset, disease duration and Expanded Disability Status Scale of Kurtzke(EDSS). As IFN-b may have stimulatory effects on immunoregulatory functionof TRAIL and all of our patients were treated with interferon beta and wereresponder, it lead to no significant change in TRAIL expression. We suggestcomparing between responders and non-responders should be investigated. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Antibodies IOS Press

Loading next page...
 
/lp/ios-press/trail-gene-expression-analysis-in-multiple-sclerosis-patients-tN59z5DJ9W

References (27)

Publisher
IOS Press
Copyright
Copyright © 2016 IOS Press and the authors. All rights reserved
ISSN
1093-2607
eISSN
1875-869X
DOI
10.3233/HAB-160291
pmid
27472871
Publisher site
See Article on Publisher Site

Abstract

BACKGROUND: Multiple sclerosis (MS) as an autoimmune disorder inwhich the insulating covers of neurons in the Central Nervous System aredestructed. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)is an immunomodulatory molecule to protect against T cells hyper activation.METHODS: In this Case-control study, we compare TRAIL geneexpression in peripheral blood between 50 relapse remitting MS patients and50 healthy controls by TaqMan Real time PCR. All the patients were negativefor HLA-DRB1*15 susceptible allele, normal serum vitamin D, responder toInterferon beta. All the health individuals were matched to patients. Also,we tried to find correlation between TRAIL gene expression and clinicalcharacteristics of patients.RESULTS: No statistically significantdifference was found in TRAIL mRNA expression between MS patients andcontrols (p> 0.05). There was no correlation in the TRAIL expression and ageof onset, disease duration and Expanded Disability Status Scale of Kurtzke(EDSS). As IFN-b may have stimulatory effects on immunoregulatory functionof TRAIL and all of our patients were treated with interferon beta and wereresponder, it lead to no significant change in TRAIL expression. We suggestcomparing between responders and non-responders should be investigated.

Journal

Human AntibodiesIOS Press

Published: Jan 1, 2016

There are no references for this article.